Dendreon Corp. (Nasdaq: DNDN) narrowed second quarter losses to 45 cents per share from 65 cents per share in the year ago period but the results were worse than expected as revenue fell and the biotechnology firm warned that Provenge sales would be flat in 2013. The stock price plummeted $1.16 to $3.43.
Dendreon Warns Of Flat Provenge Sales
August 09, 2013 at 15:12 PM EDT
